Candriam S.C.A. Decreases Stock Holdings in Centessa Pharmaceuticals PLC Sponsored ADR $CNTA

Candriam S.C.A. reduced its position in shares of Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA) by 90.8% in the first quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 36,254 shares of the company’s stock after selling 359,369 shares during the quarter. Candriam S.C.A.’s holdings in Centessa Pharmaceuticals were worth $1,440,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors have also added to or reduced their stakes in the company. Virtus Investment Advisers LLC raised its stake in shares of Centessa Pharmaceuticals by 6.2% during the fourth quarter. Virtus Investment Advisers LLC now owns 10,034 shares of the company’s stock valued at $251,000 after acquiring an additional 583 shares during the last quarter. Coastal Bridge Advisors LLC grew its stake in shares of Centessa Pharmaceuticals by 7.1% in the fourth quarter. Coastal Bridge Advisors LLC now owns 14,033 shares of the company’s stock worth $351,000 after purchasing an additional 931 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. grew its stake in shares of Centessa Pharmaceuticals by 26.4% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,688 shares of the company’s stock worth $117,000 after purchasing an additional 979 shares during the last quarter. TD Waterhouse Canada Inc. purchased a new position in Centessa Pharmaceuticals during the 4th quarter valued at about $25,000. Finally, Wells Fargo & Company MN increased its holdings in Centessa Pharmaceuticals by 42.4% during the 4th quarter. Wells Fargo & Company MN now owns 3,387 shares of the company’s stock valued at $85,000 after purchasing an additional 1,008 shares during the period. Institutional investors own 82.01% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts have weighed in on CNTA shares. Weiss Ratings reiterated a “sell (d-)” rating on shares of Centessa Pharmaceuticals in a report on Monday, April 20th. Leerink Partners cut Centessa Pharmaceuticals from an “outperform” rating to a “hold” rating and boosted their target price for the company from $36.00 to $40.00 in a research note on Wednesday, April 1st. Needham & Company LLC downgraded Centessa Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Tuesday, March 31st. Wolfe Research cut shares of Centessa Pharmaceuticals from an “outperform” rating to a “hold” rating in a research report on Tuesday, March 31st. Finally, Stephens downgraded shares of Centessa Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, March 31st. Four equities research analysts have rated the stock with a Buy rating, nine have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $41.33.

Centessa Pharmaceuticals Stock Performance

NASDAQ:CNTA opened at $40.50 on Wednesday. The firm has a market capitalization of $6.27 billion, a P/E ratio of -22.63 and a beta of 1.11. The company has a debt-to-equity ratio of 0.23, a current ratio of 9.53 and a quick ratio of 9.53. Centessa Pharmaceuticals PLC Sponsored ADR has a one year low of $12.74 and a one year high of $40.56. The company’s 50-day simple moving average is $40.00 and its 200 day simple moving average is $32.87.

Centessa Pharmaceuticals (NASDAQ:CNTA) last released its earnings results on Tuesday, May 5th. The company reported ($0.52) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.38) by ($0.14). As a group, analysts forecast that Centessa Pharmaceuticals PLC Sponsored ADR will post -1.65 EPS for the current fiscal year.

About Centessa Pharmaceuticals

Centessa Pharmaceuticals plc is a global clinical‐stage biopharmaceutical company focused on the discovery and development of innovative therapies across multiple disease areas. The company operates a modular R&D network, bringing together a portfolio of independent, specialist research entities under a single corporate umbrella. This structure is designed to accelerate decision‐making and resource allocation while leveraging deep scientific expertise in each therapeutic domain.

Centessa’s pipeline spans oncology, immunology, neuroscience, cardiovascular and metabolic diseases, as well as rare genetic disorders.